268 related articles for article (PubMed ID: 31215507)
1. Prescribing Patterns for Treatment of Mycobacterium avium Complex and M. xenopi Pulmonary Disease in Ontario, Canada, 2001-2013.
Brode SK; Chung H; Campitelli MA; Kwong JC; Marchand-Austin A; Winthrop KL; Jamieson FB; Marras TK
Emerg Infect Dis; 2019 Jul; 25(7):1271-80. PubMed ID: 31215507
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Mycobacterium Avium Complex Pulmonary Disease Treatment Completion and Adherence to ATS/IDSA Guidelines.
Ku JH; Henkle E; Carlson KF; Marino M; Brode SK; Marras TK; Winthrop KL
Clin Infect Dis; 2023 Feb; 76(3):e1408-e1415. PubMed ID: 35607719
[TBL] [Abstract][Full Text] [Related]
3. First randomised trial of treatments for pulmonary disease caused by M avium intracellulare, M malmoense, and M xenopi in HIV negative patients: rifampicin, ethambutol and isoniazid versus rifampicin and ethambutol.
Research Committee of the British Thoracic Society
Thorax; 2001 Mar; 56(3):167-72. PubMed ID: 11182006
[TBL] [Abstract][Full Text] [Related]
4. Clinical outcomes in Mycobacterium xenopi versus Mycobacterium avium complex pulmonary disease: A retrospective matched cohort study.
Zaheen A; Hirama T; Mehrabi M; Brode SK; Marras TK
Respir Med; 2020 Jun; 167():105967. PubMed ID: 32421543
[TBL] [Abstract][Full Text] [Related]
5. Tolerability Outcomes of American Thoracic Society/Infectious Diseases Society of America Guideline-Recommended Multidrug Antibiotic Treatment for Mycobacterium avium Complex Pulmonary Disease in US Medicare Beneficiaries With Bronchiectasis.
Ku JH; Henkle E; Carlson KF; Marino M; Brode SK; Marras TK; Winthrop KL
Chest; 2024 May; 165(5):1058-1069. PubMed ID: 38086472
[TBL] [Abstract][Full Text] [Related]
6. Increasing and More Commonly Refractory Mycobacterium avium Pulmonary Disease, Toronto, Ontario, Canada.
Raats D; Brode SK; Mehrabi M; Marras TK
Emerg Infect Dis; 2022 Aug; 28(8):1589-1596. PubMed ID: 35876492
[TBL] [Abstract][Full Text] [Related]
7. Lack of adherence to evidence-based treatment guidelines for nontuberculous mycobacterial lung disease.
Adjemian J; Prevots DR; Gallagher J; Heap K; Gupta R; Griffith D
Ann Am Thorac Soc; 2014 Jan; 11(1):9-16. PubMed ID: 24236749
[TBL] [Abstract][Full Text] [Related]
8. Treatment strategies with alternative treatment options for patients with Mycobacterium avium complex pulmonary disease.
Ito M; Koga Y; Hachisu Y; Murata K; Sunaga N; Maeno T; Hisada T
Respir Investig; 2022 Sep; 60(5):613-624. PubMed ID: 35781424
[TBL] [Abstract][Full Text] [Related]
9. Clinical Characteristics, Treatment Outcomes, and Resistance Mutations Associated with Macrolide-Resistant Mycobacterium avium Complex Lung Disease.
Moon SM; Park HY; Kim SY; Jhun BW; Lee H; Jeon K; Kim DH; Huh HJ; Ki CS; Lee NY; Kim HK; Choi YS; Kim J; Lee SH; Kim CK; Shin SJ; Daley CL; Koh WJ
Antimicrob Agents Chemother; 2016 Nov; 60(11):6758-6765. PubMed ID: 27572413
[TBL] [Abstract][Full Text] [Related]
10. Treatment and outcome of non-tuberculous mycobacterial pulmonary disease in a predominantly fibro-cavitary disease cohort.
Zweijpfenning S; Kops S; Magis-Escurra C; Boeree MJ; van Ingen J; Hoefsloot W
Respir Med; 2017 Oct; 131():220-224. PubMed ID: 28947034
[TBL] [Abstract][Full Text] [Related]
11. Clinical characteristics and treatment outcomes of patients with macrolide-resistant Mycobacterium avium complex pulmonary disease: a systematic review and meta-analysis.
Park Y; Lee EH; Jung I; Park G; Kang YA
Respir Res; 2019 Dec; 20(1):286. PubMed ID: 31852452
[TBL] [Abstract][Full Text] [Related]
12. Isolation of non-tuberculous mycobacteria among patients with pulmonary tuberculosis in Ontario, Canada.
Damaraju D; Jamieson F; Chedore P; Marras TK
Int J Tuberc Lung Dis; 2013 May; 17(5):676-81. PubMed ID: 23575335
[TBL] [Abstract][Full Text] [Related]
13. First line treatment selection modifies disease course and long-term clinical outcomes in Mycobacterium avium complex pulmonary disease.
Fukushima K; Kitada S; Komukai S; Kuge T; Matsuki T; Kagawa H; Tsujino K; Miki M; Miki K; Kida H
Sci Rep; 2021 Jan; 11(1):1178. PubMed ID: 33441977
[TBL] [Abstract][Full Text] [Related]
14. [Nontuberculous mycobacterial pulmonary disease - The new ATS/ERS/ESCMID/IDSA Guideline].
Wagner D; Lange C
Dtsch Med Wochenschr; 2020 Aug; 145(16):1145-1151. PubMed ID: 32791550
[TBL] [Abstract][Full Text] [Related]
15. Differences in drug susceptibility pattern between Mycobacterium avium and Mycobacterium intracellulare isolated in respiratory specimens.
Cho EH; Huh HJ; Song DJ; Moon SM; Lee SH; Shin SY; Kim CK; Ki CS; Koh WJ; Lee NY
J Infect Chemother; 2018 Apr; 24(4):315-318. PubMed ID: 29223615
[TBL] [Abstract][Full Text] [Related]
16. Role of ethambutol and rifampicin in the treatment of Mycobacterium avium complex pulmonary disease.
Kim HJ; Lee JS; Kwak N; Cho J; Lee CH; Han SK; Yim JJ
BMC Pulm Med; 2019 Nov; 19(1):212. PubMed ID: 31711459
[TBL] [Abstract][Full Text] [Related]
17. Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease.
Griffith DE; Brown-Elliott BA; Langsjoen B; Zhang Y; Pan X; Girard W; Nelson K; Caccitolo J; Alvarez J; Shepherd S; Wilson R; Graviss EA; Wallace RJ
Am J Respir Crit Care Med; 2006 Oct; 174(8):928-34. PubMed ID: 16858014
[TBL] [Abstract][Full Text] [Related]
18. Diagnosis and treatment of infections due to Mycobacterium avium complex.
Kasperbauer SH; Daley CL
Semin Respir Crit Care Med; 2008 Oct; 29(5):569-76. PubMed ID: 18810690
[TBL] [Abstract][Full Text] [Related]
19. Comparing the Genotype and Drug Susceptibilities between Mycobacterium avium and Mycobacterium intracellulare in China.
Zheng HW; Pang Y; He GX; Song YY; Zhao YL
Biomed Environ Sci; 2017 Jul; 30(7):517-525. PubMed ID: 28756811
[TBL] [Abstract][Full Text] [Related]
20. [Extracellular and intracellular activity of sparfloxacin against Mycobacterium avium complex and Mycobacterium xenopi].
Gevaudan MJ; Bollet C; Mallet MN; de Lamballerie X; Sambuc R; de Micco P
Pathol Biol (Paris); 1992 May; 40(5):443-9. PubMed ID: 1323093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
